Mihai Muraru, MD
Internal Medicine · Lebanon, INNPI 1629209317
Payments from drug & device makers
Across 141 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$280
- Amgen$273
- AbbVie$257
- GSK$224
- Bayer$202
- Novo Nordisk$142
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,592100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $280 |
| Amgen | 17 | $273 |
| AbbVie | 16 | $257 |
| GSK | 12 | $224 |
| Bayer | 9 | $202 |
| Novo Nordisk | 9 | $142 |
| Exact Sciences | 8 | $139 |
| Boehringer Ingelheim | 6 | $122 |
| Dexcom, Inc. | 5 | $118 |
| Phathom Pharmaceuticals, Inc. | 4 | $96 |
| Viatris Specialty LLC | 3 | $85 |
| AstraZeneca | 5 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Novartis | 3 | $49 |
| Harmony Biosciences LLC | 2 | $47 |
| Corcept Therapeutics | 2 | $44 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Radius Health, Inc. | 2 | $36 |
| Abiomed | 1 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Medtronic | 1 | $21 |
| Abbott | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Pfizer | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
How this compares
$2,592 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $93,133 |
| JardianceEmpagliflozin | 62 | $62,726 |
| EliquisApixaban | 39 | $48,686 |
| MounjaroTirzepatide | 21 | $25,903 |
| TrulicityDulaglutide | 20 | $22,775 |
| MyrbetriqMirabegron | 19 | $17,189 |
| JanuviaSitagliptin Phosphate | 17 | $13,308 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $11,033 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,828 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $3,327 |
| Atorvastatin Calcium | 282 | $2,407 |
| Levothyroxine Sodium | 181 | $2,261 |
| Duloxetine Hcl | 38 | $1,672 |
| Omeprazole | 70 | $1,507 |
| Potassium Chloride | 44 | $1,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $142 | $93,13375 claims |
| Boehringer IngelheimJardiance | $122 | $62,72662 claims |
| PfizerEliquis | $15 | $48,68639 claims |
| Lilly USA, LLCMounjaro, Trulicity | $280 | $48,67841 claims |
| GSKAnoro Ellipta, Trelegy Ellipta | $224 | $19,86129 claims |
| MerckJanuvia | $17 | $13,30817 claims |
| AbbVieSynthroid | $257 | $1,41832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Lebanon
- Emily FrankLebanon$100K
- Michael HornbeckerLebanon$29K
- Harold HilemanLebanon$17K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.